Roche's Parkinson's hope fails second clinical trial
An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy. The PADOVA trial of alpha-synuclein-targeting antibody …